VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2021 | Real-world findings of MRD by MFC in AML

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares an outline of the PETHEMA real-world study investigating the impact of measurable residual disease (MRD) by multiparameter flow cytometry (MFC) in patients with acute myeloid leukemia (AML). The study analyzed data from 1076 patients with AML in first remission after induction chemotherapy. Dr Paiva reports that decentralized MRD assessment after the first cycle of intensive chemotherapy shows limited clinical significance versus other prognostic factors. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter